Primary central nervous system (CNS) lymphoma in immunocompetent patients

被引：0

作者：

L. Plasswilm

U. Herrlinger

A. Korfel

M. Weller

W. Küker

L. Kanz

E. Thiel

M. Bamberg

机构：

[1] Department of Radiation-Oncology,

[2] University Hospital of Tübingen,undefined

[3] Hoppe-Seyler-Str. 3,undefined

[4] 72076 Tübingen,undefined

[5] Department of Neurology,undefined

[6] University Hospital of Tübingen,undefined

[7] Tübingen,undefined

[8] Department of Hematology,undefined

[9] Oncology,undefined

[10] and Transfusion Medicine,undefined

[11] University Hospital Benjamin Franklin,undefined

[12] Freie Universität Berlin,undefined

[13] Berlin,undefined

[14] Department of Neuroradiology,undefined

[15] University Hospital of Tübingen,undefined

[16] Tübingen,undefined

[17] Department of Hematology and Oncology,undefined

[18] University Hospital of Tübingen,undefined

[19] Tübingen,undefined

来源：

Annals of Hematology | 2002年 / 81卷

关键词：

Primary CNS lymphoma;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Primary CNS lymphoma (PCNSL) has been increasing in incidence among both immunocompetent and immunocompromised patients. Today there is no uniform approach to the treatment of this disease. Whole brain irradiation (WBI) has been standard treatment, resulting in complete remission in the majority of patients, but with most patients relapsing and dying of their disease within 2 years after treatment. The addition of chemotherapy to WBI appears to prolong survival for patients younger than 60 years with median survival reaching a plateau at approximately 40 months. The issue of the best treatment for older patients remains controversial. Prospective studies will be needed, as it is impossible to draw conclusions from the nonrandomized small series published so far. This is because the prognostic variables of age and performance status to date have affected outcome more than therapy. In this review, some of the questions regarding the management of PCNSL are addressed. Since the role of radiotherapy remains unclear, we designed a new randomized multicenter study (G-PCNSL-SG-1 trial) to investigate the optimal timing of WBI after high-dose methotrexate (HD-MTX) chemotherapy.

引用

页码：415 / 423

页数：8